Higher irradiance and photodynamic therapy for age-related macular degeneration (An AOS thesis)

Transactions of the American Ophthalmological Society

Volumn 106, Issue , 2008, Pages 357-382

  Miller, Joan W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DIMETHYL SULFOXIDE; LOW DENSITY LIPOPROTEIN; VERTEPORFIN; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLINDNESS; CONTROLLED STUDY; DENATURATION; ELECTRON MICROSCOPY; HISTOPATHOLOGY; LASER COAGULATION; MONKEY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEUROEPITHELIAL LAYER; THERMAL INJURY; VISUAL IMPAIRMENT; ANIMAL; DISEASE MODEL; FLUORESCENCE ANGIOGRAPHY; LASER; MACACA; METHODOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; PHOTOGRAPHY; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; ULTRASTRUCTURE;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; COLLAGEN; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; LASER COAGULATION; LASERS, GAS; MACACA FASCICULARIS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOGRAPHY; PHOTORECEPTOR CELLS, VERTEBRATE; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINAL PIGMENT EPITHELIUM;

EID: 63049084267     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Nanda S, Hatchell D, Tiedeman J, Dutton J, Hatchell M, McAdoo T. A new method of vascular occlusion. Photochemical initiation of thrombosis. Arch Ophthalmol 1987;105:1121-1124.
2. Miller JW, Stinson WG, Gregory WA, El-Khoumy HA, Puliafito CA. Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology 1991;98:1711-1719.
3. Kliman G, Puliafito C, Stern D, Borirakchanyavat S, Gregory W. Phthaloycyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Lasers Surg Med 1994;15:2-10.
4. Kliman G, Puliafito C, Grossman G, Gregory W. Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy. Lasers Surg Med 1994;15:11-18.
5. Miller H, Miller B. Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 1993;111:855-860.
6. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999;106:1915-1923.
7. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995;113:810-818.
8. Kramer M, Miller J, Michaud N, et al. Lipsomal BPD verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996;103:427-438.
9. Husain D, Miller J, Michaud N, Connolly E, Flotte T, Graoudas E. Intravenous infusion using liposomal benzoporphyrin derivative verteporfin for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996;114:978-985.
10. Husain D, Miller J, Kenney A, Michaud N, Flotte T, Gragroudas E. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative. Ophthalmology 1997;104:1242-1250.
11. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999;40:2322-2331.
12. van den Bergh HE, Ballini JP. Principles of photodynamic therapy. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:11-42.
13. Svaasand L, Ellingson R. Optical properties of human brain. Photochem Photobiol 1983;38:283-289.
14. Hasan T, Parish J. Photodynamic therapy of cancer. In: Holland J, ed. Cancer Medicine. 4th ed. Baltimore: Williams & Wilkins; 1997:739-751.
15. Figge F, Weiland G, Manganiello L, et al. Cancer detection and and therapy. Affinity of neoplastic, embryonic and traumatized tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 1948;68:640-641.
16. Kongshaug M. Distribution of tetrapyrrole photosensitizers among human plasma proteins. Int J Biochem 1992;24:1239-1265.
17. Jori G, Beltramini M, Reddi E, et al. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. Cancer Lett 1984;24:291-297.
18. Ginevra F, Biffanti S, Pagnan A, Biolo R, Reddi E, Jori G. Delivery of the tumour photosensitizer zinc(II)-phthalocyanine to serum proteins by different liposomes: studies in vitro and in vivo. Cancer Lett 1990;49:59-65.
19. Jori G, Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int J Biochem 1993;25:1369-1375.
20. Allison B, Pritchard P, Richter A, Levy J. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990;52:501-507.
21. Polo L, Reddi E, Garbo GM, Morgan AR, Jori G. The distribution of the tumour photosensitizers Zn(II)-phthalocyanine and Sn(IV)-etiopurpurin among rabbit plasma proteins. Cancer Lett 1992;66:217-223.
22. Kessel D. Photosensitization of neoplastic tissues with derivatives of hematoporphyrin. Photodermatol 1989;6:197-199.
23. Jori G. Low density lipoprotein-liposome delivery system for tumor photosensitizers in vivo. In: Henderson B, Dougherty T, eds. Photodynamic Therapy, Basic Principles and Clinical Applications. New York: Dekker; 1992:173-186.
24. Kessel D, Chang CK, Henderson BW. Photosensitization with methylene-linked porphyrin dimers. J Photochem Photobiol B 1993;18:177-180.
25. Gaffney J, West D, Arnold F, Sattar A, Kumar S. Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells. J Cell Sci 1985;79:317-325.
26. Ricchelli F, Gobbo S, Jori G, Moreno G, Vinzens F, Salet C. Photosensitization of mitochondria by liposome-bound porphyrins. Photochem Photobiol 1993;58:53-58.
27. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
28. Jori G, Tomio L, Reddi E, et al. Preferential delivery of liposome-incorporated porphryin to neoplastic cells in tumour-bearing rats. Br J Cancer 1983;48:307-309.
29. Allison BA, Waterfield E, Richter AM, Levy JG. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991;54:709-715.
30. Barel A, Jori G, Perin A, Romandini P, Pagnan A, Biffanti S. Role of high-, low-, and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett 1986;32:145-150.
31. Allison B, Pritchard P, Levy J. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994;69:833-839.
32. Jori G, Beltramini M, Reddi E, et al. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. Cancer Lett 1984;24:291-297.
33. West CML, West DC, Kumar S, Moore JV. A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol 1990;58:145-156.
34. Kessel D. Porphryin-lipoprotein association as a factor in porphyrin localization. Cancer Lett 1986;33:183-188.
35. Hamblin MR, Newman EL. Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J Photochem Photobiol B 1994;26:147-157.
36. Dunn KC, Marmorstein AD, Bonilha VL, Rodriguez-Boulan E, Giordano F, Hjelmeland LM. Use of the ARPE-19 cell line as a model of RPE polarity: basolateral secretion of FGF5. Invest Ophthalmol Vis Sci 1998;39:2744-2749.
37. Nguyen-Legros J, Hicks D. Renewal of photoreceptor outer segments and their phagocytosis by the retinal pigment epithelium. Int Rev Cytol 2000;196:245-313.
38. Noske UM, Schmidt-Erfurth U, Meyer C, Diddens H. Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors. Ophthalmologe 1998;95:814-819.
39. Schmidt-Erfurth U, Bauman W, Gragoudas E, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 1994;101:89-99.
40. Henderson B, Dougherty T. How does photodynamic therapy work? Photochem Photobiol 1992;55:931-948.
41. Jiang F, Allison B, Liu D, Levy J. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems. J Control Release 1992;19:41-58.
42. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 1983;130:1473-1477.
43. Goff BA, Bamberg M, Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res 1991;51:4762-4767.
44. Hu LK, Hasan T, Gragoudas ES, Young LH. Photoimmunotherapy of human uveal melanoma cells. Exp Eye Res 1995;61:385-391.
45. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004;122:1002-1011.
46. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J 2000;19:1525-1533.
47. Nelson J, Liaw L, Orenstein A, Roberts W, Berns M. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 1988;80:1599-1605.
48. Berg K, Moan J. Lysosomes and microtubules as targets for photochemotherapy of cancer. Photochem Photobiol 1997;65:403-409.
49. Fingar V. Vascular effect of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-328.
50. Matsubara A, Nakazawa T, Noda K, et al. Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model. Invest Ophthalmol Vis Sci 2007;48:4741-4747.
51. She H, Nakazawa T, Matsubara A, et al. Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2007;48:2268-2277.
52. Ju WK, Chung IW, Kim KY, et al. Sodium nitroprusside selectively induces apoptotic cell death in the outer retina of the rat. Neuroreport 2001;12:4075-4079.
53. Osborne NN, Wood JP. Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs. Invest Ophthalmol Vis Sci 2004;45:3787-3795.
54. Donovan M, Carmody RJ, Cotter TG. Light-induced photoreceptor apoptosis in vivo requires neuronal nitric-oxide synthase and guanylate cyclase activity and is caspase-3-independent. J Biol Chem 2001;276:23000-23008.
55. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90:337-341.
56. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
57. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006;113:2243-2250.
58. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
59. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007;114:2183-2189.
60. Bonnet R, Ridge R, Scourides P, et al. On the nature of hematoporphyrin derivative. J Chem Soc [Perkin 1] 1981;1:3135-3140.
61. Davidorf J, Davidorf F. Treatment of iris melanoma with photodynamic therapy. Ophthalmic Surg 1992;23:522-527.
62. Levy J. Photosensitizers in photodynamic therapy. Semin Oncol 1994;21:4-10.
63. Kato H, Horai T, Furuse K, et al. Photodynamic therapy of cancers: a clinical trial of porfimer sodium in Japan. Jpn J Cancer Res 1993;84:1209-1214.
64. Nelson JS, Roberts WG, Berns MW. In vivo studies on the utilization of mono-l-aspartyl chlorin (NPe6) for photodynamic therapy. Cancer Res 1987;47:4681-4685.
65. Schuitmaker J, van Best J, van Delft J, Dubbelman T, Oosterhuis J, de Wolff-Rouendaal D. Bacteriochlorin a, a new photosensitizer in photodynamic therapy In vivo results. Invest Ophthalmol Vis Sci 1990;31:1444-1450.
66. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991;63:87-93.
67. Moshfeghi DM, Peyman GA. Photodynamic therapy for experimental choroidal neovascularization using purlytin. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:85-88.
68. Thomas EL, Snyder WJ. Photodynamic therapy with tin ethyl etiopurpurin. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:231-237.
69. Kazi AA, Peyman GA, Unal M, et al. Threshold power levels for NPe6 photodynamic therapy. Ophthalmic Surg Lasers 2000;31:136-142.
70. Obana A, Gohto Y, Kaneda K, Nakajima S, Miki T. PDT to monkey CNV with ATX-S10(Na): inappropriateness of early laser irradiation for selective occlusion. Invest Ophthalmol Vis Sci 2001;42:2639-2645.
71. Obana A, Gohto Y, Kanai M, Nakajima S, Kaneda K, Miki T. Selective photodynamic effects of the new photosensitizer ATXS10( Na) on choroidal neovascularization in monkeys. Arch Ophthalmol 2000;118:650-658.
72. Obana A. Photodynamic therapy for experimental choroidal neovascularization using ATX-S10(Na). In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:73-83.
73. Kreimer-Birnbaum M. Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin Hematol 1989;26:157-173.
74. Morgan A, Skalkos D. Second generation sensitizers: where are we and where should we be going? Proc Soc Photo Opt Instrum Eng 1990;6:87-106.
75. Panagopoulos JA, Svitra PP, Puliafito CA, Gragoudas ES. Photodynamic therapy for experimental intraocular melanoma using chloraluminum sulfonated phthalocyanine. Arch Ophthalmol 1989;107:886-890.
76. Woodburn K, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996;14:343-348.
77. Woodburn K, Fan Q, Miles D, Kessel D, Luo Y, Young S. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem Photobiol 1997;65:410-415.
78. Arbour JD, Gauthier D. Photodynamic therapy for experimental neovascularization using Lu-Tex. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:89-97.
79. Blumenkranz MS, Woodburn K, Miller JW, Slakter JS. Photodynamic therapy with Lu-Tex: Early results. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:239-248.
80. Yoshikawa K, Kurata H, Iwahara S, Kada T. Photodynamic action of fluorescein dyes in DNA-damage and in vitro inactivation of transforming DNA in bacteria. Mutat Res 1978;56:359-362.
81. Gandin E, Lion Y, Van De Vorst A. Quantum yield of singlet oxygen production by xanthene derivatives. Photochem Photobiol 1983;37:271-278.
82. Wilson C, Hatchell D. Photodynamic retinal vascular thrombosis. Invest Ophthalmol Vis Sci 1991;32:2357-2365.
83. Royster A, Nanda S, Hatchell D, Tiedeman J, Dutton J, Hatchell M. Photochemical initiation of thrombosis. Fluorescein angiographic, histologic, and ultrastructural alterations in the choroid, retinal pigment epithelium, and retina. Arch Ophthalmol 1988;106:1608-1614.
84. Liu H, Anderson R. Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993;11:1-13.
85. Rudel LL, Lee JA, Morris MD, Felts JM. Characterization of plasma lipoproteins separated and purified by agarose-column chromatography. Biochem J 1974;139:89-95.
86. Haimovici R, Kramer M, Miller J, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997;16:83-90.
87. Waldow S, Dougherty T. Interaction of hyperthermia and photoradiation therapy. Radiat Res 1984;97:380-385.
88. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a Phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173.
89. Renno R, Delori F, Holzer R, Gragoudas E, Miller J. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2000;41:3963-3971.
90. Zacks D, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci 2002;43:2384-2391.
91. She H, Nakazawa T, Matsubara A, et al. Dexamethasone reduces photoreceptor damage caused by photodynamic therapy in a rat model of choroidal neovascularization. Invest Ophthalmol Vis Sci [published online ahread of print April 17, 2008] doi:10.1167/iovs.07-1154.
92. Richter AM, Waterfield E, Jain AK, Sternberg ED, Dolphin D, Levy JG. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990;52:495-500.
93. Kessel D. In vitro photosensitization with a benzoporphryin derivative. Photochem Photobiol 1989;49:579-582.
94. Husain D, Kramer M, Gragoudas ES, Miller JW. Angiography with verteporfin. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott, Williams & Wilkins; 2004:249-253.
95. Husain D, Gragoudas ES, Miller JW. Photodynamic therapy. In: Albert DM, Miller JW, eds. Albert and Jakobiec's Principles and Practice of Ophthalmology. 3rd ed. Philadelphia: Saunders Elsevier; 2008:1953-1961.
96. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin (VisudyneTM) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials-TAP Report #1. Arch Ophthalmol 1999;117:1329-1345.
97. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year vision results of two randomized clinical trials. TAP Report # 2. Arch Ophthalmol 2001;119:198-207.
98. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
99. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 2002;120:1443-1454.
100. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;118:327-336.
101. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in agerelated macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
102. Rosenfeld PJ, Saperstein DA, Bressler NM, et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 2004;111:1725-1733.
103. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109:1499-1505.
104. Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 2002;22:545-549.
105. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 2003;110:1315-1320.
106. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
107. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.
108. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
109. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516.
110. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140.